PHAR · Nasdaq · CIK 0001828316

Pharming Group N.V.

Pharming Group N.V.’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $376.1M and net income of $2.5M, according to its XBRL data on EDGAR. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$376.1M
Net income, FY2025
$2.5M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Pharming Group N.V.
Ticker
PHAR
SEC Central Index Key (CIK)
0001828316
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
LEIDEN, Netherlands
State or country of incorporation
Netherlands
Fiscal year ends
December 31
SEC filer category
Accelerated filer
Position in SEC ticker list
#2614 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Pharming Group N.V.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$198.9MFY2021$205.6MFY2022$245.3MFY2023$297.2MFY2024$376.1MFY2025
Net income
$16.0MFY2021$13.7MFY2022-$10.5MFY2023-$11.8MFY2024$2.5MFY2025
PHAR annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$198.9M$205.6M$245.3M$297.2M$376.1M
Net income$16.0M$13.7M-$10.5M-$11.8M$2.5M
Diluted EPS$0.02$0.02-$0.02-$0.02$0.00
Total assets$397.3M$425.8M$462.9M$400.0M$500.0M
Cash and equivalents$191.9M$207.3M$61.7M$54.9M$145.3M

XBRL tags used: revenue = RevenueFromContractsWithCustomers; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

PHAR latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Apr 2, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Oct 27, 20266-KReport of a foreign private issuer· period Oct 27, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Pharming Group N.V., by form type:

6-K ×3620-F ×220-F/A ×1SCHEDULE 13G/A ×1
PHAR recent filings
FiledFormWhat it isOriginal
Oct 27, 20266-KReport of a foreign private issuer· period Oct 27, 2026Document · Index
Oct 22, 20266-KReport of a foreign private issuer· period Oct 22, 2026Document · Index
Oct 14, 20266-KReport of a foreign private issuer· period Oct 14, 2026Document · Index
Sep 29, 20266-KReport of a foreign private issuer· period Sep 29, 2026Document · Index
Sep 25, 20266-KReport of a foreign private issuer· period Sep 25, 2026Document · Index
Sep 22, 20266-KReport of a foreign private issuer· period Sep 22, 2026Document · Index
Sep 11, 20266-KReport of a foreign private issuer· period Sep 11, 2026Document · Index
Aug 13, 20266-KReport of a foreign private issuer· period Aug 13, 2026Document · Index
Jul 30, 20266-KReport of a foreign private issuer· period Jul 30, 2026Document · Index
Jun 4, 20266-KReport of a foreign private issuer· period Jun 4, 2026Document · Index
May 28, 20266-KReport of a foreign private issuer· period May 28, 2026Document · Index
May 22, 20266-KReport of a foreign private issuer· period May 22, 2026Document · Index
May 7, 20266-KReport of a foreign private issuer· period May 7, 2026Document · Index
May 7, 20266-KReport of a foreign private issuer· period May 7, 2026Document · Index
Apr 16, 20266-KReport of a foreign private issuer· period Apr 16, 2026Document · Index
Apr 13, 202620-F/AAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Apr 2, 20266-KReport of a foreign private issuer· period Apr 2, 2026Document · Index
Apr 2, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 27, 20266-KReport of a foreign private issuer· period Mar 27, 2026Document · Index
Mar 24, 20266-KReport of a foreign private issuer· period Mar 24, 2026Document · Index
Mar 12, 20266-KReport of a foreign private issuer· period Mar 12, 2026Document · Index
Feb 3, 20266-KReport of a foreign private issuer· period Feb 3, 2026Document · Index
Feb 2, 20266-KReport of a foreign private issuer· period Feb 1, 2026Document · Index
Jan 8, 20266-KReport of a foreign private issuer· period Jan 8, 2026Document · Index
Nov 6, 20256-KReport of a foreign private issuer· period Nov 6, 2025Document · Index
Oct 22, 20256-KReport of a foreign private issuer· period Oct 20, 2025Document · Index
Oct 6, 20256-KReport of a foreign private issuer· period Oct 6, 2025Document · Index
Oct 1, 20256-KReport of a foreign private issuer· period Oct 1, 2025Document · Index
Sep 10, 20256-KReport of a foreign private issuer· period Sep 10, 2025Document · Index
Sep 2, 20256-KReport of a foreign private issuer· period Sep 2, 2025Document · Index
Jul 31, 20256-KReport of a foreign private issuer· period Jul 31, 2025Document · Index
Jun 24, 20256-KReport of a foreign private issuer· period Jun 24, 2025Document · Index
Jun 11, 20256-KReport of a foreign private issuer· period Jun 11, 2025Document · Index
May 8, 20256-KReport of a foreign private issuer· period May 8, 2025Document · Index
Apr 30, 20256-KReport of a foreign private issuer· period Apr 30, 2025Document · Index
Apr 25, 20256-KReport of a foreign private issuer· period Apr 25, 2025Document · Index
Apr 23, 20256-KReport of a foreign private issuer· period Apr 23, 2025Document · Index
Apr 7, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 3, 20256-KReport of a foreign private issuer· period Apr 3, 2025Document · Index
Apr 3, 202520-FAnnual report of a foreign private issuer· period Dec 31, 2024Document · Index

Insider filing activity

0 Form 4 filings appear in Pharming Group N.V.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001828316 and XBRL company facts. Pharming Group N.V. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.